ArticleThe Journal of pharmacology and experimental therapeutics2021
MC-100093, a Novel
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Effects of MC-100093, GLT-1 enhancer, in mesolimbic brain regions of C57BL/6 mouse exposed to hydrocodone high-dose challenge using comprehensive laboratory monitoring system.IBRO neuroscience reports · 2026Article
- MC-100093, a synthetic beta-lactam compound, and ceftriaxone modulate nicotine consumption, neuroinflammation and glutamatergic transporters in a nicotine self-administration mouse model.Psychopharmacology · 2026Article
- MC-350013 and Corylin Emerge as Promising Neuroprotective Agents through Dual Targeting of xCT and GLT-1.Journal of molecular neuroscience : MN · 2026Article
- Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats.British journal of pharmacology · 2026Article
- Modulatory effects of GLT-1 enhancer, MC-100093, on glutamate uptake and associated signaling pathways in female and male alcohol preferring rats exposed to ethanol.The international journal of neuropsychopharmacology · 2025Article
- Differential Modulation of Glutamate Transporter-1 by Cocaine and Oxycodone and the Efficacy of MC-100093 to Reduce Reinstatement of Self-Administration.Brain and behavior · 2025Article
- GlialProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Ceftriaxone and MC-100093 mitigate fentanyl-induced cardiac injury in mice: Preclinical investigation of its underlying molecular mechanisms.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Article
- Article
- Effects of novel beta-lactam, MC-100093, and ceftriaxone on astrocytic glutamate transporters and neuroinflammatory factors in nucleus accumbens of C57BL/6 mice exposed to escalated doses of morphine.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Effects of novel GLT-1 modulator, MC-100093, on neuroinflammatory and neurotrophic biomarkers in mesocorticolimbic brain regions of male alcohol preferring rats exposed chronically to ethanol.Brain research bulletin · 2024Article
- Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams.Metabolites · 2023Article
- A novel monobactam lacking antimicrobial activity, MC-100093, reduces sex-specific ethanol preference and depressive-like behaviors in mice.Neuropharmacology · 2023Article
- Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats.The Journal of pharmacology and experimental therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Lori A KnackstedtPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.) knack@ufl.edu.
Lizhen WuPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
Jeffrey RothsteinPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
Svetlana VidenskyPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
John GordonPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
Mercy RamanjuluPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
Paul DunmanPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
Benjamin BlassPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
Wayne ChildersPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
Magid Abou-GharbiaPsychology Department (L.A.K., L.W.) and Center for Addiction Research (L.A.K.), University of Florida, Gainesville, Florida; Moulder Center for Drug Discovery Research, Temple University, Philadelphia, Pennsylvania (J.G, M.R., B.B., W.C., M.A.-G.); Department of Neurology, Johns Hopkins University, Baltimore, Maryland (J.R., S.V.); and Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York (P.D.).
University of Rochester · USUniversity of Florida · USJohns Hopkins University · USTemple University · US
Funding
GLT-1 Enhancers as Drug Candidates for Treating Cocaine AddictionR01DA037270 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ABOU-GHARBIA, MAGID, ROTHSTEIN, JEFFREY D · 2014 to 2018
$2.0MNIDA NIH HHS R01 DA037270
Abstract
Cocaine use disorder currently lacks Food and Drug Administration-approved treatments. In rodents, the glutamate transporter-1 (GLT-1) is downregulated in the nucleus accumbens after cocaine self-administration, and increasing the expression and function of GLT-1 reduces the reinstatement of cocaine seeking. The
Indexed as
CocaineCocaine-Related DisordersExcitatory Amino Acid Transporter 2Rats, Sprague-DawleyAnimalsAnti-Infective Agentsbeta-LactamsDrug-Seeking BehaviorMaleNucleus AccumbensRatsRecurrenceSelf AdministrationAnti-Infective Agentsbeta-LactamsCocaineExcitatory Amino Acid Transporter 2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.